Compare · ITOC vs TMDX
ITOC vs TMDX
Side-by-side comparison of iTonic Holdings Ltd (ITOC) and TransMedics Group Inc. (TMDX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ITOC and TMDX operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- TMDX is the larger of the two at $3.25B, about 697.0x ITOC ($4.7M).
- TMDX has hit the wire 5 times in the past 4 weeks while ITOC has been quiet.
- TMDX has more recent analyst coverage (19 ratings vs 0 for ITOC).
- Company
- iTonic Holdings Ltd
- TransMedics Group Inc.
- Price
- -
- -
- Market cap
- $4.7M
- $3.25B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2024
- 2019
- News (4w)
- 0
- 5
- Recent ratings
- 0
- 19
TransMedics Group Inc.
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG, a portable perfusion, ventilation, and monitoring system that maintains the organ at a near-physiologic state allowing physicians to assess and improve the condition of lungs between the donor and recipient sites; OCS Heart, a portable, warm perfusion, and monitoring system designed to keep a donor heart at a human-like, metabolically active state; and OCS Liver, a system that is evaluated in clinical trials for utilized and unutilized donor livers. TransMedics Group, Inc. was founded in 1998 and is headquartered in Andover, Massachusetts.
Latest ITOC
- iTonic Holdings Ltd Issues an Update on its Effort to Develop AI-Powered Cloud Healthcare Platform Designed to Support Nuclear Medicine Treatment Planning and with Potential Future Expansion into Digital Care Delivery
- SEC Form 6-K filed by iTonic Holdings Ltd
- SEC Form 6-K filed by iTonic Holdings Ltd
- SEC Form 6-K filed by iTonic Holdings Ltd
- iTonic Holdings Ltd Granted An Extension of Additional 180-Day by Nasdaq to Regain Compliance with Minimum Bid Price Rule
- SEC Form 3 filed by new insider Zhang Jianfei
- Amendment: SEC Form 20-F/A filed by iTonic Holdings Ltd
- SEC Form 20-F filed by iTonic Holdings Ltd
- SEC Form 6-K filed by iTonic Holdings Ltd
- SEC Form 3 filed by new insider Zhang Pengfei
Latest TMDX
- Director Tobin James R gifted 18,000 shares (SEC Form 4)
- SEC Form 10-Q filed by TransMedics Group Inc.
- TransMedics Group Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- TransMedics Reports Second Quarter 2026 Financial Results
- TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- TransMedics to Present at the Canaccord Genuity 46th Annual Growth Conference
- UBS initiated coverage on TransMedics Group with a new price target
- TransMedics to Report Second Quarter 2026 Financial Results on August 4, 2026
- Officer Corcoran Nicholas was granted 11,727 shares, increasing direct ownership by 39% to 41,558 units (SEC Form 4)
- Chief Financial Officer Hernandez Gerardo was granted 17,246 shares, increasing direct ownership by 117% to 31,935 units (SEC Form 4)